Core Viewpoint - Crystal Technology (02228) has seen a stock increase of over 5% following the announcement of a significant clinical development milestone for the new generation PRMT5 inhibitor PEP08, which has received clinical trial approvals in Australia and Taiwan [1] Group 1: Company Developments - Crystal Technology's stock rose by 5.06%, reaching HKD 10.37, with a trading volume of HKD 964 million [1] - The company confirmed receipt of milestone payments related to the PEP08 project, which is set to enter Phase I clinical trials [1] - The AI pharmaceutical business of Crystal Technology is progressing steadily, with a projected year-on-year growth rate of 615% in drug discovery by the first half of 2025 [1] Group 2: Collaborations and Financials - Crystal Technology has established long-term collaborations with leading global pharmaceutical companies such as Pfizer and Johnson & Johnson [1] - The company signed a pipeline cooperation agreement with DoveTree, totaling USD 5.99 billion, and has received an initial payment of USD 51 million, contributing positively to its performance [1] - The company has successfully expanded its technology platform into various fields, including new energy, agriculture, and industrial materials, through the sharing of quantum physics computing, multimodal AI, and automation platforms [1]

Core Viewpoint - Crystal Technology (晶泰科技) announced a significant milestone in clinical research for the next-generation PRMT5 inhibitor PEP08, which has received clinical trial approvals from regulatory bodies in Australia and Taiwan, marking the initiation of Phase I clinical trials [1][3]. Group 1: Clinical Development - PEP08 has been approved for clinical trials by the Human Research Ethics Committee (HREC) in Australia, the Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA) [1]. - The approval signifies a major step forward in the collaboration between Crystal Technology and PharmaEngine, leading to milestone payments for Crystal Technology [1][3]. Group 2: Drug Characteristics - PRMT5 is a key enzyme overexpressed in various cancers, and inhibiting its activity can lead to a "synthetic lethality" effect in tumors with homozygous deletion of MTAP, which accounts for approximately 10-15% of human cancers [1]. - PEP08, as a second-generation PRMT5 inhibitor, exhibits high activity and selectivity, forming a stable ternary complex with PRMT5, specifically targeting MTAP-deficient tumor cells while minimizing effects on normal cells [2][3]. Group 3: Preclinical Research - Preclinical data indicate that PEP08 shows significant advantages in toxicity and safety compared to first-generation non-selective PRMT5 inhibitors, with good blood-brain barrier penetration and ideal overall drug-like properties [3]. - PEP08 demonstrates strong in vivo efficacy at lower doses in multiple animal efficacy models, suggesting potential best-in-class effects and broad potential for combination with other therapies [3].

Core Viewpoint - JingTai Technology (02228) announced a significant clinical development milestone for the next-generation PRMT5 inhibitor PEP08, which has received clinical trial approvals from regulatory bodies in Australia and Taiwan, marking the initiation of Phase I clinical trials [1][3]. Group 1: Clinical Development - PEP08 has achieved important clinical research milestones, receiving approvals from the Human Research Ethics Committee (HREC) and the Therapeutic Goods Administration (TGA) in Australia, as well as the Taiwan Food and Drug Administration (TFDA) [1]. - The project has led to milestone payments for JingTai Technology, confirming the progress made in collaboration with PharmaEngine, Inc. [1][3]. Group 2: Drug Characteristics - PRMT5 is a key enzyme overexpressed in various cancers, and inhibiting its activity can lead to a "synthetic lethality" effect in tumors with homozygous deletion of MTAP, which accounts for approximately 10-15% of human cancers [1]. - PEP08, as a second-generation PRMT5 inhibitor, exhibits high activity and selectivity, forming a stable ternary complex with PRMT5 through an MTA cooperative binding mode, specifically targeting MTAP-deficient tumor cells while minimizing effects on normal cells [2]. Group 3: Preclinical Research and Efficacy - Preclinical data indicate that PEP08 shows significant advantages in toxicity and safety compared to first-generation non-selective PRMT5 inhibitors, with good blood-brain barrier penetration and ideal overall drug-like properties [3]. - PEP08 demonstrates strong in vivo efficacy at lower doses in multiple animal efficacy models, showcasing potential best-in-class effects and broad potential for combination with other therapies [3].